Stock 300142 WALVAX BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Walvax Biotechnology Co., Ltd.

Equities

300142

CNE100000WN2

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
14.33 CNY +3.54% Intraday chart for Walvax Biotechnology Co., Ltd. +2.43% -39.05%
04-26 Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 MT
04-25 Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024
Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
China's drugmakers can't sell mRNA shots but haven't quit yet
Walvax Biotechnology's 2023 Profit Falls 42%
Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023
Walvax Biotechnology Scraps Plan to Issue Convertible Bonds
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit
Chinese Shares End Mixed as Stimulus Hopes Fade; Walvax Falls 6% on Downbeat Profit Outlook
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China
Lanvin Group Chief Executive Joann Cheng Steps Down
Walvax Biotechnology Registers Pneumonia Vaccines in Philippines
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3%
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Walvax Biotechnology's COVID-19 Vaccine Clinical Trial Results Show Efficacy, Safety
Walvax Biotechnology Chairman, Affiliates Complete Purchase of 101 Million Yuan Shares
Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300142 Stock
  4. News Walvax Biotechnology Co., Ltd.
  5. Other languages